Search results for "Italy"

showing 10 items of 2893 documents

Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.

2015

Objective:Across Italy up to 7.3% of the population is infected with hepatitis C virus (HCV), with long-term complications resulting in high medical costs and significant morbidity and mortality. Current treatment options have limitations due to side effects, interferon intolerability and ineligibility, long treatment durations and low sustained virological response (SVR) rates, especially for the most severe patients). Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir, administered with ribavirin (RBV) and with or without pegylated interferon (PEG-INF), resulted in >90% SVR across treatment-naïve (TN) genotype (GT) 1-6 patients. It is also t…

medicine.medical_specialtySofosbuvirGenotypeCost effectivenessHepatitis C virusCost-Benefit AnalysisAlpha interferonmedicine.disease_causeGastroenterologyPolyethylene GlycolAntiviral AgentsSeverity of Illness IndexTelaprevirTelaprevirPolyethylene Glycolschemistry.chemical_compoundPegylated interferonBoceprevirInternal medicineQuality-Adjusted Life YearRibavirinmedicineCost-effectiveness analysiHumansCost-Benefit AnalysiAntiviral AgentBoceprevirbusiness.industryHealth PolicyRibavirinInterferon-alphaMarkov ChainHepatitis C ChronicPatient Acceptance of Health CareVirologyChronic hepatitis C infectionMarkov ChainschemistryItalyDrug Therapy CombinationQuality-Adjusted Life YearsSofosbuvirbusinessmedicine.drugHumanJournal of medical economics
researchProduct

Reliability of EMA Binding Test in Diagnosis of Hereditary Spherocytosis in Italian Patients

2010

medicine.medical_specialtySpherocytosisSpherocytosis HereditaryGastroenterologyFluorescenceHereditary spherocytosisPredictive Value of TestsInternal medicinemedicineHumansReliability (statistics)business.industryErythrocyte MembraneHereditary Spherocytosis EMA Binding Test ROC analysisMembrane ProteinsHematologyGeneral MedicineFlow Cytometrymedicine.diseaseErythrocyte membraneItalyROC CurvePredictive value of testsEosine Yellowish-(YS)Electrophoresis Polyacrylamide Gelbusiness
researchProduct

An Update on the Role of the Quality of LDL in Cardiovascular Risk:The Contribution of the Universities of Palermo and Zurich

2007

Low density lipoproteins (LDL) size seems to be an important predictor of cardiovascular events and progression of coronary artery disease and the predominance of small dense LDL have been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. We recently showed increased LDL size or higher levels of small, dense LDL in different categories of patients at higher cardiovascular risk, such as those with coronary (including acute myocardial infarction) and non-coronary (including carotid disease, abdominal aortic aneurysm and peripheral arterial disease) forms of atherosclerosis or metabolic diseases (including type-II diabet…

medicine.medical_specialtyStatinUniversitiesmedicine.drug_classCoronary artery diseaseEzetimibeInternal medicineDrug DiscoverymedicineHumansPharmacology (medical)RosuvastatinCholesterol absorption inhibitorParticle SizeRisk factorNational Cholesterol Education Programbusiness.industrymedicine.diseasePolycystic ovaryLipoproteins LDLItalyCardiovascular DiseasesCardiologylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessSwitzerlandmedicine.drugRecent Patents on Cardiovascular Drug Discovery
researchProduct

Telemedicine during Covid-19 pandemic: Advantage or critical issue?

2020

Telemedicine offers a support to traditional medicine, delivering clinical services when distance is a critical factor. Although this tool does not replace a medical examination, during Covid-19 pandemic, it reduces the spread of infection and avoids the need for a patient’s visit. It is useful in the management of chronic disorders or for patients undergoing palliative treatment. The University Hospital of Palermo has applied this in cases of chronic illness caring for patients who cannot stop their treatment, such as Department of Onco-Haematology, Internal Medicine, Dermatology, etc. The Department of Legal Medicine of Palermo, in particular, is also using telemedicine to manage medico-…

medicine.medical_specialtyTelemedicinePalliative careCoronavirus disease 2019 (COVID-19)Pneumonia ViralHealth Services AccessibilityPublic health serviceBetacoronavirus03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegalePandemicHumansMedicine030216 legal & forensic medicine030212 general & internal medicineDisease management (health)PandemicsSARS-CoV-2business.industryCommunicationPalliative CareMedical jurisprudenceCOVID-19Disease ManagementGeneral Medicinemedicine.diseaseTelemedicineTelemedicine covid 19 clinical servicesOutpatient visitsItalyChronic DiseaseMedical emergencyCoronavirus InfectionsbusinessMedico-Legal Journal
researchProduct

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

2020

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the first European country to face the first wave of infection outside mainland China. The first case of COVID-19 was confirmed in Lombardy on February 20th , 2020, and subsequently, a rapid increase in the number of detected cases was observed, spreading through Italy and the rest of Europe.3 As of April 22nd , confirmed COVID-19 cases in Italy were 183,957.

medicine.medical_specialtyTildrakizumabBiolgical therapy; COVID-19; PsoriasisSettore MED/35PsoriasisChronic Disease; Emergencies; Humans; Italy; Psoriasis; Biological Therapy; COVID-19UstekinumabmedicineAdalimumabHumansPsoriasisbiologicsIntensive care medicineLetter to the Editorpsoriasipsoriasis; biologics; covid-19; pandemicEmergenciePsoriasiRisankizumabbusiness.industrySARS-CoV-2pandemicBiolgical therapyCOVID-19medicine.diseasedermatologyBiological TherapyIxekizumabGuselkumabInfectious Diseasescovid-19ItalyChronic DiseaseSecukinumabEmergenciesbusinessSettore MED/35 - MALATTIE CUTANEE E VENEREEbiologicCOVID-19 psoriasis biological therapiesmedicine.drugHuman
researchProduct

Optimal savings and health spending over the life cycle

2010

This paper investigates the relationship between saving and health spending in a two-period overlapping generations economy. Individuals work in the first period of life and live in retirement in old age. Health spending is an activity that increases quality of life and longevity. Empirical evidence shows that both health spending and saving behave as luxury goods but their behaviour differs markedly according to the level of per capita GDP. The share of saving on GDP has a concave shape with respect to per capita GDP, whereas the share of health spending on GDP increases more than proportionally with respect to per capita GDP. The ratio of saving to spending is nonlinear with respect to in…

medicine.medical_specialtyTime FactorsHealth spendingEconomics Econometrics and Finance (miscellaneous)Decision MakingIntertemporal choiceOverlapping generations modelIntertemporal choiceGross domestic productStatistics NonparametricResource AllocationMicroeconomicsCost SavingsEconomicsmedicineHumansEmpirical evidenceSettore SECS-P/01 - Economia Politicahealth care economics and organizationsHealth economicsModels StatisticalAdult mortalitySavingPublic healthHealth PolicyModels EconomicReal gross domestic productItalyQuality of LifeHealth ResourcesDemographic economicsIntertemporal choice; Health spending; Adult mortality; SavingHealth ExpendituresPublic finance
researchProduct

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

2013

Abstract Background Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of osteoporosis; one of their adverse effects is the osteonecrosis of the jaw (BRONJ). The primary endpoints of this multi-center cross-sectional study are: i) an observation of the clinical features of BRONJ in 87 osteoporotic, non-cancer patients; and ii) an evaluation of their demographic variables and comorbidities. Methods 87 BRONJ patients in therapy for osteoporosis with BPs from 8 participating clinical Italian centers were consecutively identified and studied. After BRONJ diagnosis and staging, comorbidities and data relating to local and drug-related risk factors for BRONJ were col…

medicine.medical_specialtyTime FactorsMultivariate analysisHeart DiseasesOsteoporosisSettore MED/50 - Scienze Tecniche Mediche ApplicateAdministration OralMandibleOsteonecrosis jawHospital based studyAdrenal Cortex HormonesRisk FactorsSettore MED/28 - Malattie OdontostomatologicheInternal medicineDiabetes MellitusInternal MedicinemedicineHumansIn patientRisk factorOral bisphopshonateAdverse effectOsteoporosis PostmenopausalAgedRetrospective StudiesAged 80 and overAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryLiver DiseasesIncidence (epidemiology)Age FactorsMiddle Agedmedicine.diseaseSurgeryCross-Sectional StudiesItalyOral bisphopshonates; Osteonecrosis jaws; OsteoporosisHypertensionMultivariate AnalysisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusiness
researchProduct

Use of Marginal Donors in Kidney Transplantation: Our Experience

2006

The use of elderly donors has been advocated to expand the organ donor pool because of increased needs and the organ shortage. The aim of this study was to analyze whether the use of elderly donors and marginal kidneys affected the outcome of renal transplantations. Herein we presented data on 126 kidney transplantations performed from January 1996 to September 2003 using 32 marginal donors (group A) and 94 ideal donors (group B). We analyzed the medical and surgical complications and the graft survivals at a median follow-up of 18 months. Medical and surgical complications occurred in 22% and 5% versus 7% and 4% in groups A and B, respectively. The mean cold ischemia time and the mean age …

medicine.medical_specialtyTime FactorsWaiting ListsEconomic shortageelderly patientsCold Ischemia TimeGroup BPostoperative ComplicationsCadaverHumansMedicineDonor poolKidney transplantationMarginal donorRetrospective StudiesTransplantationKidneybusiness.industryGraft SurvivalMean agemedicine.diseaseKidney TransplantationTissue DonorsSurgeryTreatment Outcomemedicine.anatomical_structureItalySurgeryGraft survivalbusinessFollow-Up StudiesTransplantation Proceedings
researchProduct

AISF position paper on HCV in immunocompromised patients.

2018

Abstract This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.

medicine.medical_specialtyTransplant RecipientComorbidityAntiviral AgentsOrgan transplantation03 medical and health sciencesImmunocompromised Host0302 clinical medicineInternal medicineNeoplasmsmedicineImmunocompromised patientHumansChronicIntensive care medicineAntiviral AgentHepatologybusiness.industryGastroenterologyHepatologyHepatitis C Chronicmedicine.diseaseComorbidityHepatitis COrgan transplantHCV; Immunocompromised patients; Organ transplant; Hepatology; GastroenterologyTransplant RecipientsHCV; Immunocompromised patients; Organ transplant; Antiviral Agents; Comorbidity; Hepatitis C Chronic; Humans; Immunocompetence; Italy; Neoplasms; Transplant Recipients; Immunocompromised HostItaly030220 oncology & carcinogenesisHCVHCV Immunocompromised patients Organ transplantPosition paperNeoplasmImmunocompromised patients030211 gastroenterology & hepatologyImmunocompetencebusinessImmunocompetenceDirect actingHumanDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

What Is the Impact of Innovative Electronic Health Interventions in Improving Treatment Adherence in Asthma? The Pediatric Perspective

2019

Suboptimal adherence to treatment is a significant issue in the management of pediatric asthma and is a major cause of uncontrolled disease, life-threatening attacks, and increased utilization of healthcare resources. Electronic health (e-Health) solutions have the potential to positively impact asthma self-management in children and adolescents and their families, thereby improving treatment adherence and asthma outcomes. However, there is a lack of sufficient data to support widespread adoption of e-Health tools in pediatric asthma practice. A critical evaluation of the impact of these new interventions on treatment adherence in childhood asthma must consider unmet needs, heterogeneity of…

medicine.medical_specialtyTreatment adherencePsychological interventionMobile applicationDiseaseElectronic monitoring devicesPediatrics03 medical and health sciences0302 clinical medicineMobile applicationsInventionsAsthma controlHealth caremedicineHumansImmunology and Allergy030212 general & internal medicineChildIntensive care medicinemHealthChildrenAsthmaChildhood asthmabusiness.industryPerspective (graphical)medicine.diseaseQuality ImprovementTelemedicineAsthmaTreatment Adherence and ComplianceItaly030228 respiratory systemElectronic monitoring deviceAdherencee-Healthbusiness
researchProduct